Tafamidis for treating transthyretin amyloidosis with cardiomyopathy: Appraisal consultation document

DRAFT guidance does not recommend use because of inconsistent results on how effective it is for different types and stages of disease, difficulty determining who benefits from treatment and who should stop, and resulting uncertainty on cost effectiveness.


National Institute for Health and Care Excellence